Kadimastem Receives Approval of Patent Registration for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in a Third Territory Sep 28, 2022 07:00AM
ILEX Medical to Invest 10 million NIS ($3.2 million) in Kadimastem Nov 29, 2021 07:00AM
Kadimastem Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS Mar 9, 2021 07:00AM
Kadimastem Announces Executive Management Changes Feb 1, 2021 07:00AM
Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS Aug 3, 2020 07:00AM